首页> 外文期刊>Journal of the American Oil Chemists' Society >Clinical applications of C18 and C20 chain length polyunsaturated fatty acids and their biotechnological production in plants.
【24h】

Clinical applications of C18 and C20 chain length polyunsaturated fatty acids and their biotechnological production in plants.

机译:C18和C20链长多不饱和脂肪酸的临床应用及其在植物中的生物技术生产。

获取原文
获取原文并翻译 | 示例

摘要

A potential revolution in FA therapies is on the horizon. In recent years, the full magnitude of various FA treatments and their overall importance to health has become increasingly apparent. Fetal and infant nutrition studies have clearly shown that FA status at birth can have life-long health implications affecting eye and brain function, insulin resistance, and blood pressure control. As well, nutrition studies have identified dietary imbalances and deficiencies that have the potential to alter the health of future generations severely and to promote progression of age-related degenerative disorders. Mixtures of naturally occurring FA have shown promise as therapeutic agents for a diverse range of health conditions including atopic eczema, rheumatoid arthritis, cardiovascular disease, and neurological problems. Through the 1990s, the creation of technologies to concentrate and formulate pharmacologically active individual FA components as well as tailored combinations propelled development of this new drug category. However, high production costs and government regulatory encumbrance limited the expansion of this emerging pharmaceutical sector. Fortunately, many countries are now creating regulatory frameworks that are better suited for product evaluation and control of the manufacturing FA products than historical drug models, and hence expansion in this area is now anticipated..
机译:FA治疗的潜在革命即将到来。近年来,各种FA治疗的全面范围及其对健康的总体重要性已日益明显。胎儿和婴儿的营养研究清楚地表明,出生时FA的状态可能会影响一生,影响眼睛和大脑功能,胰岛素抵抗和血压控制。营养研究还发现,饮食失衡和缺乏症有可能严重改变后代的健康并促进与年龄有关的变性疾病的发展。天然脂肪酸的混合物已显示出有望作为多种健康状况的治疗剂,包括特应性湿疹,类风湿性关节炎,心血管疾病和神经系统疾病。在整个1990年代,集中和配制具有药理活性的FA成分的技术创造以及量身定制的组合推动了这一新药物类别的发展。但是,高昂的生产成本和政府的监管限制限制了这一新兴制药行业的扩张。幸运的是,与历史上的药物模型相比,许多国家/地区现在正在创建更适合于产品评估和生产FA产品的控制的监管框架,因此现在可以预见该领域的扩展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号